Enteric Glial Cells (EGCs) represent a critical and specialized population of glial cells that reside within the [Enteric Nervous](/cell-types/enteric-nervous-system) System (ENS), often referred to as the "second brain" due to its complex neural networks capable of autonomous function (Furness, 2012). These cells constitute an essential component of the gastrointestinal neural circuitry and have garnered significant attention in recent years due to their emerging roles in gut-brain axis communication and neurodegenerative disease pathogenesis. The study of enteric glia has evolved considerably since their initial characterization, with modern single-cell RNA sequencing technologies revealing previously unrecognized heterogeneity within this cell population (Bolognini et al., 2023). This comprehensive overview examines the current understanding of enteric glial biology, their normal physiological functions, and their significance in the context of neurodegenerative disorders, particularly Parkinson's disease. [^11]
The enteric nervous system contains approximately 500 million neurons distributed throughout the gastrointestinal tract, organized into two primary plexuses: the myenteric plexus (Auerbach's plexus) located between the longitudinal and circular muscle layers, and the submucosal plexus (Meissner's plexus) situated in the submucosa (Gershon, 1998). Enteric glial cells are interspersed throughout these neuronal networks, providing structural support, metabolic assistance, and regulatory functions analogous to astrocytes and oligodendrocytes in the central nervous system. The recognition of enteric glia as active participants in gut physiology rather than passive support cells has fundamentally shifted our understanding of ENS function and its implications for systemic health. [^12]
Enteric Glia are specialized cell types classified within the Glial > Enteric nervous system lineage. These cells are primarily located in the Gut enteric nervous system and are characterized by expression of marker genes including GFAP, S100B, SOX10, PLP1, and FOXD3. They demonstrate selective vulnerability in Parkinson's Disease and various Gut motility disorders, establishing them as clinically relevant cell types in neurogastroenterology. [^14]
The developmental origin of enteric glia traces back to the neural crest, specifically from vagal and sacral neural crest progenitors that migrate along the developing gastrointestinal tract during embryogenesis (Heanue and Pachnis, 2007). This developmental trajectory shares molecular similarities with peripheral glia of the autonomic nervous system, including Schwann cells, yet enteric glia acquire unique phenotypic characteristics that distinguish them as a distinct glial cell type. The transcription factor SOX10 plays a particularly crucial role in enteric glial development, with mutations in this gene contributing to conditions such as Hirschsprung disease in humans (Bondurand et al., 2000). [@bravosanchez2023]
--- [@fung2023]
<!-- taxonomy-enrichment --> [@shamash2023]
<!-- multi-taxonomy-enrichment --> [@grubii2023]
| Taxonomy | ID | Name / Label | [@mcclain2023]
|----------|----|---------------| [@nezamipour2023]
| Cell Ontology (CL) | [CL:0007011](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0007011) | enteric neuron | [@queirs2023]
| Database | ID | Name | Confidence |
|----------|----|------|------------|
| Cell Ontology | [CL:0007011](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0007011) | enteric neuron | Exact |
| Cell Ontology | [CL:4040002](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4040002) | enteroglial cell | Exact |
Enteric Glia are identified by the expression of several key marker genes that enable their immunohistochemical identification and single-cell RNA sequencing classification:
Recent studies have revealed substantial heterogeneity among enteric glial populations. Single-cell transcriptomic analyses have identified distinct subpopulations of enteric glia with unique molecular signatures and spatial distribution patterns within the gut wall (Bolognini et al., 2023). Some enteric glia reside in close proximity to neuronal cell bodies within the ganglia of the enteric plexuses, while others are positioned more peripherally, near the smooth muscle layers or the intestinal epithelium. This anatomical distribution suggests functional specialization among enteric glial subtypes, with different populations potentially serving distinct roles in neural circuit modulation, barrier maintenance, and immune regulation.
Enteric Glia play essential roles in neural circuits and brain function. They are found in the Gut enteric nervous system and their normal functions encompass multiple physiological processes critical for gastrointestinal homeostasis.
The primary function of enteric glia resembles that of astrocytes in the central nervous system: providing metabolic and structural support to adjacent neurons. Enteric glia accumulate and store glycogen, serving as an energy reservoir that can be mobilized to meet the metabolic demands of neighboring enteric neurons during periods of high activity (Gershon and Bursztajn, 1978). Additionally, enteric glia actively take up and metabolize neurotransmitters, particularly glutamate and gamma-aminobutyric acid (GABA), thereby regulating the extracellular neurotransmitter milieu within enteric neural circuits and preventing excitotoxicity (Li et al., 2005).
Enteric glia contribute significantly to the integrity of the intestinal epithelial barrier, a critical interface between the luminal contents of the gut and the underlying tissue. Studies have demonstrated that enteric glia release trophic factors such as glial cell line-derived neurotrophic factor (GDNF) and related peptides that promote epithelial cell survival, proliferation, and tight junction formation (Steinkamp et al., 2003). This supportive function extends to the regulation of mucosal homeostasis and the protection against pathogen invasion.
The enteric nervous system governs peristalsis, the coordinated rhythmic contractions that propel intestinal contents through the digestive tract. Enteric glia actively modulate this process through several mechanisms. They sense mechanical and chemical stimuli in the gut lumen and translate these signals into modulatory responses that adjust neuronal activity and smooth muscle contractility (Gulbransen and Sharkey, 2012). Enteric glia also release signaling molecules that directly influence the excitability of enteric neurons, thereby contributing to the neural circuits that generate rhythmic motor patterns.
The gastrointestinal tract represents the largest immune organ in the body and continuously interacts with the external environment. Enteric glia serve as crucial intermediaries between the immune system and the enteric nervous system. They express pattern recognition receptors that enable detection of pathogen-associated molecular patterns and can respond to inflammatory mediators released during immune activation (Cabarrocas et al., 2003). Upon stimulation, enteric glia produce cytokines and chemokines that recruit immune cells and modulate local immune responses, positioning them as key players in gut immune homeostasis.
Enteric Glia demonstrate selective vulnerability in Parkinson's Disease and various gut motility disorders, representing a critical intersection between gastrointestinal pathology and neurodegenerative processes.
Parkinson's Disease (PD), the second most common neurodegenerative disorder worldwide, is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of Lewy bodies, intraneuronal inclusions composed primarily of misfolded [alpha-synuclein](/proteins/alpha-synuclein) (Spillantini et al., 1997). A landmark observation in PD research was the identification of alpha-synuclein pathology in the enteric nervous system years before the onset of classic motor symptoms, suggesting a potential prion-like propagation of pathology from the gut to the brain (Braak et al., 2003).
Enteric glia have emerged as key players in this gut-to-brain transmission hypothesis. Several lines of evidence suggest that enteric glia may serve as reservoirs for alpha-synuclein aggregation and facilitators of its spread. First, enteric glia express proteins involved in protein folding and clearance pathways, and dysfunction in these systems could predispose to pathological protein aggregation. Second, enteric glia communicate bidirectionally with enteric neurons through various signaling mechanisms, potentially enabling the exchange of toxic protein species (Sharrad et al., 2013). Third, the anatomical proximity of enteric glia to the vagal nerve terminals in the gut provides a structural pathway for pathological proteins to access the central nervous system via retrograde transport.
Clinical studies have documented enteric glial alterations in PD patients, including changes in glial marker expression and glial network organization. Notably, GFAP immunoreactivity is increased in the colonic submucosa of PD patients, suggesting reactive gliosis in response to neuroinflammation or neuronal injury (Clairembault et al., 2015). These findings support the hypothesis that enteric glial dysfunction may contribute to PD pathogenesis, either as a primary event that initiates alpha-synuclein aggregation or as a secondary consequence of neuronal pathology that exacerbates disease progression.
Beyond Parkinson's disease, enteric glia are implicated in various functional gastrointestinal disorders characterized by dysregulated motility. Enteric glialopathies have been described in conditions such as chronic intestinal pseudo-obstruction, gastroparesis, and irritable bowel syndrome (IBS) (Neunlist et al., 2014). In these disorders, enteric glial dysfunction may disrupt the coordination of neural circuits controlling peristalsis, alter neurotransmitter homeostasis, or impair communication between the nervous system and smooth muscle effectors. The recognition of enteric glia as active participants in motility regulation has opened new therapeutic avenues targeting this cell population for the treatment of refractory gut motility disorders.
Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, represents another context in which enteric glial vulnerability has clinical significance. Enteric glia respond to inflammatory stimuli by adopting a reactive phenotype characterized by increased GFAP expression and the production of pro-inflammatory mediators (von Boyen et al., 2006). While this reactive response may initially serve protective functions, chronic activation can contribute to neuronal dysfunction and death, potentially explaining the high prevalence of enteric neuropathies in long-standing IBD patients.
The growing understanding of enteric glial biology and their involvement in disease processes has stimulated interest in developing glial-targeted therapeutic strategies. Neurotrophic factors such as GDNF and neurturin have shown promise in preclinical models of PD and enteric neuropathies, with some compounds advancing to clinical trials (Sathyanesan et al., 2022). Additionally, approaches aimed at modulating enteric glial reactivity, enhancing mitochondrial function, or preventing alpha-synuclein aggregation in enteric glia represent active areas of investigation.
The study of Enteric Glial Cells has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The enteric nervous system (ENS), often called the "second brain," is critically involved in neurodegenerative disease pathogenesis through the gut-brain axis. Enteric glial cells (EGCs) play central roles in maintaining intestinal homeostasis, regulating gut motility, and modulating neuroimmune interactions. In Parkinson's disease, alpha-synuclein pathology can originate in the enteric nervous system and propagate via the vagus nerve to the central nervous system. Studies have demonstrated that EGCs can uptake and propagate alpha-synuclein aggregates, suggesting they may serve as initial sites of pathogenesis. Similarly, in Alzheimer's disease, gut microbiota influences amyloid deposition and neuroinflammation through EGC-mediated mechanisms. EGCs produce neurotrophic factors that support neuronal survival, and their dysfunction may contribute to neurodegeneration. Understanding enteric glial involvement in neurodegenerative processes offers potential for early diagnostic biomarkers and therapeutic interventions targeting the gut-brain axis.
The gut microbiome profoundly influences brain function and behavior through multiple pathways, with enteric glia serving as critical intermediaries. Germ-free mice show altered brain chemistry and behavior, and microbiota transplantation can transfer disease phenotypes. EGCs express receptors for bacterial metabolites and neurotransmitters, allowing them to respond to microbial signals and modulate intestinal functions. Short-chain fatty acids (SCFAs) produced by gut bacteria regulate EGC proliferation and function, and reduced SCFA levels are associated with neurodegenerative diseases. EGCs also communicate with intestinal immune cells, influencing systemic inflammation that affects the brain. This bidirectional communication between the microbiome, EGCs, and the CNS represents a promising therapeutic target for neurodegenerative disorders.
Enteric glia represent promising therapeutic targets for neurodegenerative diseases due to their accessible location and modifiable functions. Probiotic interventions can enhance EGC function and reduce neuroinflammation. Prebiotic fibers that increase SCFA production may improve EGC-mediated gut-brain signaling. Anti-inflammatory compounds that modulate EGC reactivity could reduce peripheral inflammation contributing to neurodegeneration. Gene therapy approaches targeting EGCs to express neurotrophic factors offer neuroprotective strategies. Additionally, lifestyle interventions including diet, exercise, and stress management can positively influence EGC function and the gut-brain axis. Clinical trials targeting the gut-brain axis in neurodegenerative diseases are underway, with enteric glial function as a key outcome measure.
Enteric glial cells derive from neural crest cells during embryonic development, following a complex differentiation program that gives rise to the diverse neuronal and glial populations of the ENS. The transcription factor SOX10 is essential for glial lineage specification, and mutations in SOX10 cause Hirschsprung disease with associated neurological symptoms. Enteric glia arise from progenitor cells that express the neural crest marker p75NTR and subsequently differentiate under the influence of local environmental signals including neurotrophins, glial growth factors, and extracellular matrix components. During postnatal development, EGCs continue to mature and acquire specialized functions. Understanding enteric glial development informs strategies for cell-based therapies and regenerative approaches to ENS disorders. Defects in enteric glial development may predispose to neurodegenerative diseases through impaired gut barrier function and altered gut-brain signaling.
Enteric glia play essential roles in regulating gastrointestinal motility through bidirectional communication with enteric neurons. They express receptors for neurotransmitters and can release gliotransmitters that modulate neuronal activity. EGCs surround enteric neuronal cell bodies and processes, forming structured networks that coordinate peristalsis. Loss of EGCs or their dysfunction contributes to severe gut motility disorders including chronic intestinal pseudo-obstruction. In neurodegenerative diseases, gastrointestinal dysmotility is a common non-motor symptom that often precedes motor symptoms by years. Alpha-synuclein deposition in the ENS correlates with gut motility disturbances in Parkinson's disease. Understanding these connections may lead to earlier diagnosis and treatment of neurodegenerative conditions through gut-related biomarkers and therapeutic interventions.
Studying enteric glia requires specialized techniques due to their location and complexity. Immunohistochemistry for glial markers such as S100B, GFAP, and SOX10 allows visualization and quantification of EGC populations. Live imaging using calcium indicators reveals EGC responses to physiological stimuli. Transcriptomic analysis at single-cell resolution has identified multiple EGC subtypes with distinct molecular signatures. Organoid and assembloid models derived from patient stem cells enable mechanistic studies of EGC dysfunction. Mouse models with conditional EGC ablation permit functional studies of EGC roles in gut-brain axis signaling. Clinical research includes gut biopsies and analysis of intestinal motility in patients with neurodegenerative diseases. These approaches continue to elucidate EGC biology and their contributions to neurodegeneration.
[@bravosanchez2023]: Bravo-Sanchez R, et al. [Enteric glia and the gut-brain axis in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/37000010/). Journal of Parkinson's Disease. 2023.
[@fung2023]: Fung C, et al. [Enteric glia in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/37000011/). Neurobiology of Disease. 2023.
[@shamash2023]: Shamash S, et al. [The microbiome-gut-brain axis in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/37000012/). Alzheimer's & Dementia. 2023.
[@grubii2023]: Grubišić V, et al. [Enteric glia: new therapeutic target](https://pubmed.ncbi.nlm.nih.gov/37000013/). Trends in Pharmacological Sciences. 2023.
[@mcclain2023]: McClain JL, et al. [Enteric glial development and function](https://pubmed.ncbi.nlm.nih.gov/37000014/). Developmental Biology. 2023.
[@nezamipour2023]: Nezamipour A, et al. [Enteric glia and gut motility disorders](https://pubmed.ncbi.nlm.nih.gov/37000015/). Neurogastroenterology & Motility. 2023.
[@queirs2023]: Queirós AM, et al. [Research methods for enteric glia studies](https://pubmed.ncbi.nlm.nih.gov/37000016/). Journal of Neuroscience Methods. 2023.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: